Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its ...

Aconcagua Bio Inc. has divulged calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone and ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

A particular focus is on once-weekly oral GLP-1 and amylin therapies for weight loss. The company’s drug development pipeline centers around harnessing emerging knowledge of gut-brain biology to ...

The other two assets in Verdiva’s pipeline are a once-weekly oral amylin agonist and a long-acting, subcutaneous amylin agonist. The plan is to start a phase 2 study of the GLP-1 agonist this ...

The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. BioWorld ...

Verdiva also has two earlier-stage amylin programs, including one that is orally available and dosed weekly and another that is subcutaneously formulated. Both amylin assets can be used alone or with ...

A more apt comparison would be between HS-10535 and Viking's own (still unnamed) pre-clinical weight loss program -- a dual amylin and calcitonin receptor agonist. Amylin is a hormone that helps ...

Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target ...